Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting

Nasdaq Flags Jupiter Neurosciences for Bid Price and Market Value Listing Deficiencies

Jupiter Neurosciences to Present Clinical and Commercial Progress at Mar-a-Lago Investor Dinner

Jupiter Neurosciences Delays Yorkville Note Installments to April 1, 2026

Jupiter Neurosciences Amends Yorkville Financing Agreement Terms

Jupiter Neurosciences Amends Yorkville Convertible Notes to Delay Monthly Payments Until April 2026

Jupiter Neurosciences Inc - Announces Strategic Initiative for Glp-1 Users

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City

Jupiter Neurosciences Secures $1.86 Million Second Tranche Financing from Yorkville

Jupiter Neurosciences Inc. Held Annual Shareholder Meeting

Jupiter Neurosciences to Present at NobleCon21 Emerging Growth Conference

BRIEF-Jupiter Neurosciences Files Rospectus Related To Resale Of Up To 10 Million Shares Of Our Common Stock By Selling Stockholder

Jupiter Neurosciences Inc - Files Rospectus Related to Resale of up to 10 Mln Shares of Our Common Stock by Selling Stockholder

Jupiter Neurosciences Issues Amended SEC Filing

Jupiter Neurosciences price target lowered to $25 from $30 at Greenridge

Jupiter receives FDA clearance of IND application to initiate Phase 2 trial

BRIEF-Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson’s Disease

Jupiter Neurosciences Inc - Expects Trial Enrollment to Begin in Early 2026